This study shows that well-validated symptom surveys could be used by doctors to identify suggestive symptom patterns that could lead to the diagnosis of PTLDS.
An antibody biomarker was recently discovered that identifies people with chronic skeletal muscle disease and severe heart muscle involvement.
A survey of more than 600 people with myositis from the US, Korea, and Sweden identified 5 aspects of living with the disease that are most important to patients.
A new study found that people with scleroderma who have muscle weakness due to the accumulation of fibrous tissue in their muscles, are at risk for severe disease outcomes including death from heart disease.
A collaborative effort between Rheumatology and Oncology offers guidance to doctors treating patients for inflammatory arthritis caused by treatment with “immune checkpoint inhibitors”, a type of cancer therapy.
A study lead by Lisa Christopher-Stine, M.D., M.P.H. identified “Hiker’s Feet” as a new skin finding in some patients with inflammatory muscle disease (myositis).
Younger patients with a specific form of myositis associated with antibodies to a protein called HMGCR have a worse prognosis than older patients.
Medical record review of patients admitted to the Johns Hopkins Hospital over 20-years, revealed that pneumocystis jiroveci pneumonia infection is a rare but persistent risk for patients with rheumatic diseases.
Dr. Myma Albayda with the Johns Hopkins Arthritis Center highlights what’s involved in a joint injection.